In the era of immunotherapy, programmed cell death 1 (PD−1)/PD−ligand 1 (PD−L1) has been shown to be a biomarker for cancer diagnosis and prediction of response to immunotherapy, but is not sufficiently sensitive. This evidence concerns the gene CD274 and cancer.